## **Targets**

# Hands-on-training

Part 1: Upstream analysis workflow in geneXplain platform


Part 2: Look and feel of Genome Enhancer software

### Part 1

Run a complete upstream analysis with the geneXplain platform.


Part 1 – Run a complete upstream analysis with the geneXplain platform.

Open the Upstream analysis (TRANSFAC(R)) and TRANSPATH® workflow as shown below.




#### Part 1 – Run a complete upstream analysis with the geneXplain platform.

Navigate to the *GSM558469\_E2F1\_hg19* filtered exp1000 dist1000 L<600 track and drag-and-drop it to the **Input Yes track** field of the workflow input mask. Navigate to the *Housekeeping genes* (*Human*) track -100000 to -98000 filtered chr 1 track and drag-and-drop it to the **Input No track** field of the workflow input mask. The field **Sequence source** should be set to Ensembl Human 75 genome build. Click **Run workflow** when parameters are set as shown below.



#### Part 1 – Run a complete upstream analysis with the geneXplain platform.


Have a look to the results folder and corresponding files.





#### Part 2 – Genome Enhancer tour

Genome Enhancer page in your browser: <a href="https://genexplain-platform.com/bioumlweb/">https://genexplain-platform.com/bioumlweb/</a>


Specify your credentials and click **Login**.
























#### Part 1 – Genome Enhancer tour

Have a look to the results with clicking **Brief Tale** and **Full Story**.



















### Report on promising druggable targets and drugs for treating Hepatitis C that are identified on the basis of analysis of differentially expressed genes in liver tissue

Demo User geneXplain GmbH info@genexplain.com Project IFN-alpha induction (GSE31193) --- Transcriptomics, LogFC Table Data received on 13/08/2019; Run on 26/10/2020; Report generated on 26/10/2020

Based on the performed analysis, the following drugs were proposed as most promising candidates for treating the pathology under study: Naloxone, Tofacitinib and Perindopril.

These drugs were selected for acting on the following targets: TLR4, JAK2 and ITGA2B. The targets were identified by analysis of molecular mechanism of the pathology under study.

Proposed drugs are top ranked drug candidates, that were found to be active on the identified targets and were selected from 4 categories:

- FDA approved drugs or used in clinical trials drugs for the studied pathology;
- 2. Repurposing drugs used in clinical trials for other pathologies;
- 3. Drugs, predicted by PASS to be active against identified drug targets and against the studied pathology;
- 4. Drugs, predicted by PASS to be active against identified drug targets but for other pathologies.

Proposed drugs were selected on the basis of Drug rank which was computed from two scores:





Sequence and Pathway analysis

TLR4 and CCND3 are promising druggable targets for treating Hepatitis C that control activity of IRF7, EP300 and E2F1 transcription factors on promoters of differentially expressed genes in liver tissue

Demo User geneXplain GmbH info@genexplain.com

Data received on 13/08/2019; Run on 26/10/2020; Report generated on 26/10/2020

Genome Enhancer release 2.2 (TRANSFAC®, TRANSPATH® and HumanPSD™ release 2020.3)









#### Part 1 – Genome Enhancer Help page

Click the link below and read through the description of the Genome Enhancer Software.

https://ge.genexplain.com/bioumlweb/ge/help/step-project.shtml

## **Practical session completed**